Status:
RECRUITING
Cannabis Abstinence and Neurocognitive Assessment in Adolescence
Lead Sponsor:
University Hospital Pilsen
Conditions:
Cannabis Dependence
Harmful Use
Eligibility:
All Genders
15-18 years
Brief Summary
Cannabis Abstinence and Neurocognitive Assessment in Adolescence
Detailed Description
Evaluate the development of cognitive functions following attainment of abstinence in a group of adolescents with cannabis dependence or harmful cannabis use. Abstinence is confirmed by toxicological ...
Eligibility Criteria
Inclusion
- Adolescents aged 15-18 years with a diagnosis of cannabis dependence or harmful cannabis use.
Exclusion
- psychiatric comorbidity - Dual diagnosis, including psychotic disorders, mood disorders, severe organic brain damage, or autism spectrum disorder, with the exception of compensated and stabilized anxiety disorder. Psychopharmacological treatment is permitted, except for antipsychotics prescribed for psychosis.
- somatic comorbidity - Severe endocrine disorders such as diabetes mellitus, thyroid dysfunction, or severe cardiovascular disease.
- Violation of abstinence between the first and second neuropsychological assessments, as well as severe decompensation of mental state requiring modification of established psychopharmacological treatment.
Key Trial Info
Start Date :
December 3 2024
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
August 31 2029
Estimated Enrollment :
29 Patients enrolled
Trial Details
Trial ID
NCT07160153
Start Date
December 3 2024
End Date
August 31 2029
Last Update
September 19 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Hospital Pilsen
Pilsen, Czechia, Czechia, 30100